Kiniksa Pharmaceuticals/$KNSA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Ticker
$KNSA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
315
ISIN
GB00BRXB0C07
Website
KNSA Metrics
BasicAdvanced
$2.1B
-
-$0.24
0.31
-
Price and volume
Market cap
$2.1B
Beta
0.31
52-week high
$30.69
52-week low
$17.38
Average daily volume
648K
Financial strength
Current ratio
3.659
Quick ratio
3.171
Long term debt to equity
1.666
Total debt to equity
2.167
Profitability
EBITDA (TTM)
-14.228
Gross margin (TTM)
54.38%
Net profit margin (TTM)
-3.52%
Operating margin (TTM)
-3.28%
Effective tax rate (TTM)
-168.58%
Revenue per employee (TTM)
$1,530,000
Management effectiveness
Return on assets (TTM)
-1.77%
Return on equity (TTM)
-3.81%
Valuation
Price to revenue (TTM)
4.259
Price to book
4.53
Price to tangible book (TTM)
4.7
Price to free cash flow (TTM)
46.856
Free cash flow yield (TTM)
2.13%
Free cash flow per share (TTM)
60.80%
Growth
Revenue change (TTM)
59.45%
Earnings per share change (TTM)
-291.46%
3-year revenue growth (CAGR)
89.48%
3-year earnings per share growth (CAGR)
-50.50%
What the Analysts think about KNSA
Analyst ratings (Buy, Hold, Sell) for Kiniksa Pharmaceuticals stock.
Bulls say / Bears say
Kiniksa Pharmaceuticals reported a 75% increase in ARCALYST revenue in Q1 2025, indicating strong market adoption and potential for continued growth. (nasdaq.com)
The company has provided guidance for 2025 ARCALYST net product revenue between $560 million and $580 million, reflecting confidence in sustained revenue growth. (globenewswire.com)
Kiniksa's cash, cash equivalents, and short-term investments increased to $243.6 million as of December 31, 2024, providing a strong financial foundation for future operations. (nasdaq.com)
Despite increased revenue, Kiniksa reported a net loss of $8.9 million in Q4 2024, raising concerns about profitability. (nasdaq.com)
Total operating expenses for Q4 2024 were $141.8 million, a significant increase from $83.3 million in Q4 2023, which may impact future profitability. (nasdaq.com)
The company's accumulated deficit reached $521.1 million as of December 31, 2024, indicating ongoing financial challenges. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
KNSA Financial Performance
Revenues and expenses
KNSA Earnings Performance
Company profitability
KNSA News
AllArticlesVideos
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
GlobeNewsWire·3 weeks ago
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewsWire·4 weeks ago
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kiniksa Pharmaceuticals stock?
Kiniksa Pharmaceuticals (KNSA) has a market cap of $2.1B as of June 27, 2025.
What is the P/E ratio for Kiniksa Pharmaceuticals stock?
The price to earnings (P/E) ratio for Kiniksa Pharmaceuticals (KNSA) stock is 0 as of June 27, 2025.
Does Kiniksa Pharmaceuticals stock pay dividends?
No, Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Kiniksa Pharmaceuticals dividend payment date?
Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals (KNSA) has a beta rating of 0.31. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.